Hemispherian: Difference between revisions
Created from NHT member research |
Created with researched data |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:Hemispherian}} | ||
|name=Hemispherian | {{Infobox company | ||
| | | name = Hemispherian AS | ||
| | | org_number = 925333409 | ||
| | | founded = 2020-06-15 | ||
|funding= | | employees = 5 | ||
| | | address = Norway | ||
| industry = 72.100 – Biotechnology research | |||
| website = https://hemispherian.com | |||
| nht_category = Startup | |||
| description = Hemispherian is an innovative clinical-stage pharmaceutical company developing a novel class of small molecule drugs targeting the TET2 enzyme as a targeted therapy for particularly aggressive cancers. TET2 is a DNA demethylase enzyme linked to cancer progression when mutated or dysregulated. | |||
| notes = No disclosed revenue or funding. 5 employees. Clinical-stage means active drug development pipeline. | |||
| related_companies = [[IC Targets]], [[Exact Therapeutics]], [[Seald]], [[Norway Health Tech]] | |||
| categories = Norway Health Tech, Startups, Biotechnology, Oncology, Drug Development | |||
| sources = https://hemispherian.com; https://data.brreg.no/enhetsregisteret/api/enheter/925333409 | |||
}} | }} | ||
== | == About == | ||
Hemispherian AS is a Norwegian clinical-stage pharmaceutical company developing novel small molecule drugs targeting the TET2 enzyme for the treatment of aggressive cancers. | |||
== | == Technology == | ||
Hemispherian's drug development approach focuses on the TET2 (Ten-Eleven Translocation 2) enzyme — a DNA demethylase that plays a critical role in epigenetic regulation. Dysregulation or mutation of TET2 is implicated in the progression of various aggressive cancers. The company is developing a novel class of small molecules that target TET2 as a therapeutic strategy. | |||
[[Category: | == Pipeline == | ||
[[Category: | |||
Hemispherian is at the clinical-stage, indicating active development toward or within clinical trials. The company has published key publications related to its scientific approach. | |||
== References == | |||
<references/> | |||
[[Category:Norway Health Tech]] | |||
[[Category:Startups]] | |||
[[Category:Biotechnology]] | |||
[[Category:Oncology]] | |||
[[Category:Drug Development]] | |||
Latest revision as of 20:14, 14 April 2026
About[edit]
Hemispherian AS is a Norwegian clinical-stage pharmaceutical company developing novel small molecule drugs targeting the TET2 enzyme for the treatment of aggressive cancers.
Technology[edit]
Hemispherian's drug development approach focuses on the TET2 (Ten-Eleven Translocation 2) enzyme — a DNA demethylase that plays a critical role in epigenetic regulation. Dysregulation or mutation of TET2 is implicated in the progression of various aggressive cancers. The company is developing a novel class of small molecules that target TET2 as a therapeutic strategy.
Pipeline[edit]
Hemispherian is at the clinical-stage, indicating active development toward or within clinical trials. The company has published key publications related to its scientific approach.